10-Q: Mosaic ImmunoEngineering Q1 2026 Financials Show Cash Concerns

Mosaic ImmunoEngineering, Inc. reported its first-quarter 2026 financial results, highlighting a significant decrease in cash and cash equivalents and continued operational losses, underscoring the critical need for future capital raises.

Summary

• Mosaic ImmunoEngineering, Inc. filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $175,351 for the three months ended March 31, 2026, compared to a net loss of $181,320 for the same period in 2025.
• Cash and cash equivalents significantly decreased to $72 as of March 31, 2026, from $3,622 as of December 31, 2025.
• Total current assets decreased to $9,828 from $19,882.
• Total liabilities increased to $7,661,199 from $7,495,902.
• The company's ability to continue operations is highly dependent on its ability to raise capital, as current cash on hand is insufficient for the next twelve months.
• Management is actively seeking financing and business development opportunities, including debt financings, equity offerings, and potential partnering arrangements.
• The company has no current arrangements for additional financing, and there is no assurance that such financing will be available on commercially reasonable terms, or at all.
• The company's operations may be curtailed or cease completely if adequate funds are not available.
• The company's prior attempt to acquire rights from Oncotelic Therapeutics, Inc. via a binding term sheet expired on June 30, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the critical liquidity situation, the explicit statement of doubt regarding the going concern, and the lack of any secured future financing, despite ongoing efforts.

Positives

• Research and development expenses remained relatively stable at $15,880 for Q1 2026 compared to $15,803 for Q1 2025, indicating continued focus on core activities.
• General and administrative expenses decreased by approximately $20,000 in Q1 2026 compared to Q1 2025, attributed to reduced accounting/filing fees, lower payroll costs, and decreased director/officer insurance.
• The company earned $14,000 in other income during the three months ended March 31, 2025, from advisory and related services under a Master Services Agreement with Oncotelic, which expired February 28, 2025.

Negatives

• Cash and cash equivalents plummeted to $72 as of March 31, 2026, from $3,622 as of December 31, 2025, indicating severe liquidity constraints.
• The company reported a net loss of $175,351 for the quarter ended March 31, 2026.
• Total current assets decreased significantly to $9,828 from $19,882.
• Total liabilities increased to $7,661,199 from $7,495,902.
• The company explicitly states that its cash on hand will not satisfy operational and capital requirements for the next twelve months.
• There are substantial doubts regarding the company's ability to continue as a going concern.
• The company has no current arrangements for additional financing and cannot assure the availability of future funding.
• Failure to obtain adequate capital could lead to curtailment or cessation of operations.
• Any future equity financing may result in substantial dilution to existing stockholders.

Risks

• The company's ability to continue operations is highly dependent on its ability to raise capital to fund future operations, and current cash on hand is insufficient for the next twelve months.
• There are a number of uncertainties associated with the company's ability to raise additional capital, and no current arrangements exist for additional financing.
• There can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed.
• The inability to obtain additional capital will delay the company's ability to conduct its business operations.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• If adequate funds are not available on acceptable terms, or at all, the company will need to curtail operations, or cease operations completely.
• The continuation of disruptions caused by COVID-19 or other related variants, broad-based inflation, and potential recession may cause investors to slow down or delay their decision to deploy capital, adversely impacting the company's ability to fund future operations.
• The company may be involved in various lawsuits and claims arising in the ordinary course of business, which could have a material adverse effect on its business, financial condition, results of operations, and/or cash flows.
• The company has made certain guarantees and indemnities under which it may be required to make payments, although no liabilities have been recorded for these historically.
• The resolution of the claim regarding escrowed shares from the Crossflo acquisition may result in a material obligation to the company, though not currently recorded.

Future Outlook

The company anticipates that its current cash on hand will not satisfy its operational and capital requirements through the next twelve months from the filing date. Management is actively pursuing financing and business development opportunities. However, there are significant uncertainties regarding the ability to raise additional capital, and no assurance can be given that such financing will be available on commercially reasonable terms, or at all. Failure to secure adequate funding could lead to curtailment or cessation of operations.

Management Comments

• Management is actively engaged in discussions with potential investors and strategic partners and is pursuing a range of financing and business development opportunities that may include debt financings, equity offerings, and potential partnering arrangements.
• These efforts are intended to secure the capital necessary to support the Company's ongoing operations and advance its development programs.
• No assurances can be given as to the Company's ability to execute its plan to raise additional capital to fund ongoing operations or that available debt or equity financing will be available on favorable terms, if at all.
• If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.
• The above matters raise substantial doubt regarding our ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Mosaic ImmunoEngineering operates in the highly capital-intensive biotechnology sector, where early-stage companies often face significant challenges in securing ongoing funding. The current financial results, with extremely low cash reserves and substantial operating losses, are typical of development-stage biotech firms. However, the severity of the cash crunch and the lack of current financing arrangements place Mosaic ImmunoEngineering in a precarious position, requiring immediate and successful capital infusion to avoid operational cessation.

Comparison to Industry Standards

• Development-stage biotechnology companies often operate with negative cash flow and rely on external financing. However, Mosaic ImmunoEngineering's cash and cash equivalents of $72 at the end of Q1 2026 is exceptionally low, even for this sector.
• Companies like Moderna and BioNTech, while also in the immunotherapy space, have achieved significant market capitalization and revenue streams through successful product development and commercialization, a stage Mosaic ImmunoEngineering has not yet reached.
• The critical need for capital raises is a common theme, but the lack of current arrangements and the explicit mention of potential operational cessation highlight a more acute liquidity crisis than typically seen in standard industry reports for companies with active development programs.
• The company's net loss of $175,351 for the quarter is modest compared to the substantial R&D investments made by larger, more established biotechs, but it represents a significant burn rate relative to its minimal cash reserves.

Legal Proceedings

• While the Company is not involved in any litigation as of March 31, 2026, it may be involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any litigation could have a material adverse effect on the Company's business, financial condition, results of operations, and/or cash flows.

Related Party Transactions

• Consulting agreements were in place with Nicole Steinmetz, Ph.D., Jonathan Pokorski, Ph.D., and Steve Fiering, Ph.D., for scientific contributions. During the three months ended March 31, 2026 and 2025, no related party consulting expenses were incurred.
• Accrued consulting fees of $264,375 were recorded as of March 31, 2026, and December 31, 2025, for services provided by these related parties.
• Former Board members invested in convertible notes: $225,000 in aggregate in the May 2021 issuance and $155,000 in aggregate in the February 2022 issuance.
• Steven King, President and CEO, is a shareholder, board member, and paid advisor of Oncotelic Therapeutics, Inc., with whom a binding term sheet was previously entered into.

Stakeholder Impact

• Shareholders face significant risk of dilution from potential future equity financings and the potential for complete loss of investment if the company ceases operations due to lack of funding.
• Employees may face uncertainty regarding job security if the company is forced to curtail or cease operations.
• Creditors and suppliers may face risks of non-payment if the company cannot secure additional funding.
• The company's ability to advance its immunotherapy pipeline impacts potential future patients and the broader healthcare ecosystem.

Next Steps

• Management is actively seeking to raise additional capital through debt financings, equity offerings, and potential partnering arrangements.
• The company needs to secure sufficient capital to fund ongoing operations and advance its development programs.
• If adequate funds are not secured, the company may need to curtail or cease operations.

Key Dates

Recommendation

The company is in a critical liquidity situation with substantial doubt about its going concern status. While there are ongoing efforts to secure financing, the lack of current arrangements and the severe cash depletion make it a high-risk investment. However, the core technology and potential of immunotherapies warrant a 'hold' for existing investors who can tolerate extreme risk, while new investment is not recommended until significant financing is secured and operational viability is more certain.

Keywords

Mosaic ImmunoEngineering, 10-Q, Quarterly Report, Biotechnology, Immunotherapy, Cancer Treatment, Financial Statements, Loss from Operations, Cash Flow, Going Concern, Capital Raise, Dilution, SEC Filing